Acetylcysteine
- Generic Name
- Acetylcysteine
- Brand Names
- Acetadote
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9NO3S
- CAS Number
- 616-91-1
- Unique Ingredient Identifier
- WYQ7N0BPYC
- Background
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
- Indication
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
- Associated Conditions
- Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
- Associated Therapies
- Airway secretion clearance therapy
N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Queen Mary Hospital, Hong Kong
- Target Recruit Count
- 80
- Registration Number
- NCT05706402
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Teny Tjitra Sari
- Target Recruit Count
- 16
- Registration Number
- NCT05611086
- Locations
- 🇮🇩
Dr Cipto Mangunkusumo National Hospital, Jakarta Pusat, DKI Jakarta, Indonesia
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, N-Acetylcysteine)
- Conditions
- Cocaine Use DisorderOpioid Use Disorder
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- William Stoops
- Target Recruit Count
- 24
- Registration Number
- NCT05610072
- Locations
- 🇺🇸
University of Kentucky Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States
🇺🇸University of Kentucky Department of Behavioral Science, Lexington, Kentucky, United States
Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD
- Conditions
- NAFLD
- Interventions
- Behavioral: Diet and exercise
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT05576428
Efficacy of NAC for the Prevention and Relief of PIPN in Women With Ovarian, Tubal, and Peritoneal Cancer
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05539053
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
Oral N-acetylcysteine for Retinitis Pigmentosa
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 438
- Registration Number
- NCT05537220
- Locations
- 🇺🇸
University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California, United States
🇺🇸University of Southern California, Keck School of Medicine, Los Angeles, California, United States
🇺🇸University of California - San Francisco, Department of Ophthalmology, San Francisco, California, United States
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
- Conditions
- Acetaminophen OverdoseDrug-induced Liver InjuryLiver ToxicityDrug OverdoseLiver FailureAcetaminophenAcetaminophen Poisoning
- Interventions
- Drug: Intravenous infusion of Fomepizole (4-MP)
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Richard Dart, MD, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT05517668
- Locations
- 🇺🇸
Denver Health and Hospital Authority, Denver, Colorado, United States
A Randomised Controlled Trial, of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Western Sydney Local Health District
- Target Recruit Count
- 160
- Registration Number
- NCT05509153
- Locations
- 🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺The University of Queensland, Herston, Queensland, Australia
🇦🇺Calvary Health Care Bethlehem, Parkdale, Victoria, Australia
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 48
- Registration Number
- NCT05494398
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
- Conditions
- Drug Resistant Epilepsy
- Interventions
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 45
- Registration Number
- NCT05485558
- Locations
- 🇪🇬
Tanta University, Tanta, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.